CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice[S] by Fatiha Nassir, Okunade L. Adewole, Elizabeth M. Brunt, Nada A. Abumrad

Get full text

Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. by Rebecca C Schugar, Xiaojing Huang, Ashley R Moll, Elizabeth M Brunt, Peter A Crawford

Get full text

Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. by Qing-Rong Chen, Rosemary Braun, Ying Hu, Chunhua Yan, Elizabeth M Brunt, Daoud Meerzaman, Arun J Sanyal, Kenneth Buetow

Get full text

Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial(†)(†)This trial is posted on clinicaltrials.gov (NCT00267670). This research was su... by Lisa B. Van Wagner, Sean W.P. Koppe, Elizabeth M. Brunt, Jeanne Gottstein, Konstantina Gardikiotes, Richard M. Green, Mary E. Rinella, M.D.

Get full text

Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease by Erin E. Elbel, Joel E. Lavine, Michael Downes, Mark Van Natta, Ruth Yu, Jeffrey B. Schwimmer, Cynthia Behling, Elizabeth M. Brunt, James Tonascia, Ronald Evans

Get full text

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. by Victor J Navarro, Steven H Belle, Massimo D'Amato, Nezam Afdhal, Elizabeth M Brunt, Michael W Fried, K Rajender Reddy, Abdus S Wahed, Stephen Harrison, Silymarin in NASH and C Hepatitis (SyNCH) Study Group

Get full text

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. by Victor J Navarro, Steven H Belle, Massimo D'Amato, Nezam Adfhal, Elizabeth M Brunt, Michael W Fried, K Rajender Reddy, Abdus S Wahed, Stephen Harrison, Silymarin in NASH and C Hepatitis (SyNCH) Study Group

Get full text